Cargando…
Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is being developed as a drug for the treatment of estrogen receptor (ER) positive breast cancer. Endoxifen is known to be a potent anti-estrogen and its mechanisms of action are still being elucidated. Here, we demonstrate that endoxifen-me...
Autores principales: | Hawse, John R., Subramaniam, Malayannan, Cicek, Muzaffer, Wu, Xianglin, Gingery, Anne, Grygo, Sarah B., Sun, Zhifu, Pitel, Kevin S., Lingle, Wilma L., Goetz, Matthew P., Ingle, James N., Spelsberg, Thomas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557294/ https://www.ncbi.nlm.nih.gov/pubmed/23382923 http://dx.doi.org/10.1371/journal.pone.0054613 |
Ejemplares similares
-
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
por: Wu, Xianglin, et al.
Publicado: (2011) -
The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
por: Gingery, Anne, et al.
Publicado: (2014) -
SUN-LB135 Estrogen Receptor Beta Inhibits NFkB Signaling to Inhibit Triple Negative Breast Cancer
por: Aspros, Kirsten, et al.
Publicado: (2020) -
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
por: Reese, Jordan M, et al.
Publicado: (2014) -
TIEG1/KLF10 Modulates Runx2 Expression and Activity in Osteoblasts
por: Hawse, John R., et al.
Publicado: (2011)